Evidence map›Paper›PMID 34488765›Full record

ArticleMicrobial cell factories2021

The iSplit GFP assay detects intracellular recombinant proteins in Bacillus subtilis.

Patrick Lenz, Fabienne Hilgers, Alina Burmeister, Leonie Zimmermann, Kristina Volkenborn, Alexander Grünberger, Dietrich Kohlheyer, Thomas Drepper, Karl-Erich Jaeger, Andreas Knapp

Open access · goldAbstract read
In one paragraph

Article in Microbial cell factories, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Synthesis and characterization of titanium dioxide nanoparticles fromFrontiers in bioengineering and biotechnology · 2023
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Patrick LenzInstitute of Molecular Enzyme Technology, Heinrich Heine University Düsseldorf, Forschungszentrum Jülich, 52425, Jülich, Germany.
Fabienne HilgersInstitute of Molecular Enzyme Technology, Heinrich Heine University Düsseldorf, Forschungszentrum Jülich, 52425, Jülich, Germany.
Alina BurmeisterInstitute of Bio- and Geoscience, IBG-1: Biotechnology: Forschungszentrum Jülich GmbH, 52425, Jülich, Germany.
Leonie ZimmermannInstitute of Molecular Enzyme Technology, Heinrich Heine University Düsseldorf, Forschungszentrum Jülich, 52425, Jülich, Germany.
Kristina VolkenbornInstitute of Molecular Enzyme Technology, Heinrich Heine University Düsseldorf, Forschungszentrum Jülich, 52425, Jülich, Germany.
Alexander GrünbergerInstitute of Bio- and Geoscience, IBG-1: Biotechnology: Forschungszentrum Jülich GmbH, 52425, Jülich, Germany.
Dietrich KohlheyerInstitute of Bio- and Geoscience, IBG-1: Biotechnology: Forschungszentrum Jülich GmbH, 52425, Jülich, Germany.
Thomas DrepperInstitute of Molecular Enzyme Technology, Heinrich Heine University Düsseldorf, Forschungszentrum Jülich, 52425, Jülich, Germany.
Karl-Erich JaegerInstitute of Molecular Enzyme Technology, Heinrich Heine University Düsseldorf, Forschungszentrum Jülich, 52425, Jülich, Germany.
Andreas KnappInstitute of Molecular Enzyme Technology, Heinrich Heine University Düsseldorf, Forschungszentrum Jülich, 52425, Jülich, Germany. a.knapp@fz-juelich.de.ORCID http://orcid.org/0000-0002-2759-6313
Forschungszentrum Jülich · DE

Funding

european regional development fund 34.EFRE-0300096Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen 313/323-400-00213
6 · The paper itself

Abstract

backgroundBacillus subtilis is one of the most important microorganisms for recombinant protein production. It possesses the GRAS (generally recognized as safe) status and a potent protein secretion capacity. Secretory protein production greatly facilitates downstream processing and thus significantly reduces costs. However, not all heterologous proteins are secreted and intracellular production poses difficulties for quantification. To tackle this problem, we have established a so-called intracellular split GFP (iSplit GFP) assay in B. subtilis as a tool for the in vivo protein detection during expression in batch cultures and at a single-cell level. For the iSplit GFP assay, the eleventh β-sheet of sfGFP is fused to a target protein and can complement a detector protein consisting of the respective truncated sfGFP (GFP1-10) to form fluorescent holo-GFP.

resultsAs proof of concept, the GFP11-tag was fused C-terminally to the E. coli β-glucuronidase GUS, resulting in fusion protein GUS11. Variable GUS and GUS11 production levels in B. subtilis were achieved by varying the ribosome binding site via spacers of increasing lengths (4-12 nucleotides) for the GUS-encoding gene. Differences in intracellular enzyme accumulation were determined by measuring the GUS11 enzymatic activity and subsequently by adding the detector protein to respective cell extracts. Moreover, the detector protein was co-produced with the GUS11 using a two-plasmid system, which enabled the in vivo detection and online monitoring of glucuronidase production. Using this system in combination with flow cytometry and microfluidics, we were able to monitor protein production at a single-cell level thus yielding information about intracellular protein distribution and culture heterogeneity.

conclusionOur results demonstrate that the iSplit GFP assay is suitable for the detection, quantification and online monitoring of recombinant protein production in B. subtilis during cultivation as well as for analyzing production heterogeneity and intracellular localization at a single-cell level.

Indexed as

Bacillus subtilisBacterial ProteinsEscherichia coliGlucuronidaseRecombinant ProteinsBacterial ProteinsGlucuronidaseRecombinant ProteinsBacillus subtilisFlow cytometryIntracellular proteiniSplit GFP assayMicrofluidicsOnline monitoringβ-glucuronidase

Identifiers

PMID34488765
PMCPMC8419962
OpenAlexW3198550284

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.